紫杉醇化疗联合参一胶囊对晚期非小细胞肺癌患者的疗效及安全性

Efficacy and Safety of Shenyi Capsule Combined with Paclitaxel in Treating Patients with Non-small Cell Lung Cancer

目的:探讨紫杉醇化疗联合参一胶囊对晚期非小细胞肺癌(Non-small-cell Carcinoma,NSCLC)患者的疗效及安全性,为NSCLC临床治疗提供可参考依据。方法:选择2010年1月至2013年3月100例我院初诊为晚期NSCLC的患者作为研究对象,根据患者意向性分为观察组与对照组,观察组给予紫杉醇联合参一胶囊治疗,对照组仅给予紫杉醇单独化疗治疗。比较观察2组患者的近远期临床疗效及不良反应的发生情况。同时采用酶联免疫吸附法检测血管内皮生长因子(VEGF)水平。结果:观察组总有效率67.9%明显高于对照组47.7%,2组比较差异有统计学意义(P<0.05)。观察组患者1年、2年生存率分别为42.9%、25.0%,均明显高于对照组22.7%、9.1%,且观察组平均生存时间亦长于对照组,差异有统计学意义(P<0.05)。治疗后2组VEGF水平均有明显降低,与治疗前相比差异有统计学意义(P<0.05),且观察组VEGF水平降低更明显(P<0.05)。结论:紫杉醇化疗联合参一胶囊可以明显增加化疗治疗NSCLC的疗效,延长NSCLC患者的生存时间,且对降低VEGF水平有积极作用,值得临床推广应用。

Objective： To evaluate the efficacy and adverse reactions of Shenyi capsule combined with paclitaxel in the treatment of patients with non-small cell lung cancer（ NSCLC）. Methods： A hundred patients with NSCLC admitted in in the hospital from January 2010 to March 2013 were included. All patients were divided into observation group and control group according to the intention of patients. Patients in observation group were given Shenyi capsule combined with paclitaxel treatment,and patients in control group were given paclitaxle treatment sorely. The long term survival and adverse reactions were observed and compared between the two groups. At the same time,the level of vascular endothelial growth factor（ VEGF） was detected and compared using enzymelinked immunosorbent method. Results： The total effective rate in observation group was 67. 9%,which was higher than that of 47.7% in control group. The difference is statistically significant（ P 〈0. 05）. The 1 year,2 year survival rates in observation group were 42. 9% and 25. 0%,which were higher than 22. 7% and 9. 1% in the control group. The difference is statistically significant（ P 〈0. 05）. The average survival time in observation group was longer than that of the control group,and the differences was statistically significant（ P〈 0. 05）. The VEGF levels after treatment in two groups were lower than those before treatment and the difference is statistically significant（ P〈 0. 05）. The VEGF levels in observation group after treatment were lower than that of the control group,and the difference is statistically significant（ P〈 0. 05）. Conclusion： Shenyi capsule combined with paclitaxel can prolong the survival time,improve quality of life to patients with NSCLC. Also,it can low the levels of VEGF,which is worthy of clinical promotion.